{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Science Desk", "lead_paragraph": "A new exploration of how evolution works at the genomic level may have a significant impact on drug development and other areas of medicine. The report, published in Nature last week, offers new evidence in a longstanding debate about how organisms evolve. One well-known path to change is a heavily favorable mutation in a single gene. But it may be well known only because it is easy to study. Another path is exploitation of mildly favorable differences that already exist in many genes.", "headline": {"main": "Natural Selection Cuts Broad Swath Through Fruit Fly Genome"}, "abstract": "Report in journal Nature finds that genetic change in fruit flies is caused by process know as soft sweep, in which many genes influence newly emerged trait; scientists have long hoped that such change could be attributed to relatively few target genes, which would make diseases easier to treat; University of California, Irvine, biologists Molly K Burke, Michael R Rose and Anthony D Long led fruit fly stud (M)", "print_page": "3", "word_count": 783, "_id": "4fd29aa88eb7c8105d87a4d4", "snippet": "A new exploration of how evolution works at the genomic level may have a significant impact on drug development and other areas of medicine.     The report, published in Nature last week, offers new evidence in a longstanding debate about how...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9800E5DF143FF932A1575AC0A9669D8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "ROSE, MICHAEL R"}, {"name": "persons", "value": "BURKE, MOLLY K"}, {"name": "persons", "value": "LONG, ANTHONY D"}, {"name": "organizations", "value": "NATURE"}, {"name": "organizations", "value": "UNIVERSITY OF CALIFORNIA"}, {"name": "subject", "value": "GENETICS AND HEREDITY"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "FRUIT FLIES"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Nicholas", "rank": 1, "lastname": "WADE"}], "original": "By NICHOLAS WADE"}, "document_type": "article", "pub_date": "2010-09-21T00:00:00Z", "section_name": "Science; Health"}, {"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": "The race to replace the decades-old anti-coagulant warfarin, a drug to treat an irregular heartbeat disorder called atrial fibrillation, heats up in earnest on Monday as a cardiology advisory panel at the Food and Drug Administration meets to consider a new drug, dabigatran, from Boehringer Ingelheim.", "headline": {"main": "The Week Ahead in Health Industry News", "kicker": "Prescriptions"}, "abstract": "A cardiology advisory panel at the Food and Drug Administration reviews a new heart drug. Insurers must adopt some provisions of the health overhaul law starting Thursday.", "print_page": null, "word_count": 543, "_id": "4fd39c428eb7c8105d8dbed9", "snippet": "A cardiology advisory panel at the Food and Drug Administration reviews a new heart drug. Insurers must adopt some provisions of the health overhaul law starting Thursday.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://prescriptions.blogs.nytimes.com/2010/09/20/the-week-ahead-in-health-industry-news-2/", "multimedia": [], "subsection_name": null, "keywords": [{"value": "News", "name": "type_of_material", "rank": "1"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Natasha", "lastname": "SINGER"}], "original": "By NATASHA SINGER"}, "document_type": "blogpost", "pub_date": "2010-09-20T10:47:03Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "National", "lead_paragraph": "Two cousins developed the same lethal cancer; only one could take part in an experimental drug trial. Critics say that new science behind the drugs has eclipsed the old rules, and ethics, of testing them.", "headline": {"kicker": "Target Cancer", "main": "New Drugs Stir Debate on Rules of Clinical Trials", "sub": "Path to a Second Trial ;", "print_headline": "When Testing a Drug Means Withholding It", "content_kicker": "Target Cancer"}, "abstract": null, "print_page": "1", "word_count": "4110", "_id": "541ac27d79881037000b9cee", "snippet": "Two cousins developed the same lethal cancer; only one could take part in an experimental drug trial. Critics say that new science behind the drugs has eclipsed the old rules, and ethics, of testing them.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2010/09/19/health/research/19trial.html", "multimedia": [{"subtype": "xlarge", "url": "images/2010/09/19/us/19trial1_span/trial-1-articleLarge.jpg", "height": 330, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2010/09/19/us/19trial1_span/trial-1-articleLarge.jpg", "xlargeheight": "330"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2010/09/19/us/19trial1_span/trial-1-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2010/09/19/us/19trial1_span/trial-1-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": "Research", "keywords": [{"value": "Clinical Trials", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Regulation and Deregulation of Industry", "is_major": "N", "rank": "11", "name": "subject"}, {"value": "Ethics", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Cancer", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Melanomas", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Medicine and Health", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Chemotherapy", "is_major": "N", "rank": "7", "name": "subject"}, {"value": "Doctors", "is_major": "N", "rank": "8", "name": "subject"}, {"value": "Food and Drug Administration", "is_major": "N", "rank": "9", "name": "organizations"}, {"value": "Roche Holding AG", "is_major": "N", "rank": "10", "name": "organizations"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Amy", "lastname": "HARMON"}], "original": "By AMY HARMON"}, "document_type": "article", "pub_date": "2010-09-19T00:00:00Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "The Food and Drug Administration appears to have postponed an expected decision on whether to revoke the approval of the drug Avastin as a treatment for breast cancer. Genentech, the manufacturer of the drug, said on Friday that the F.D.A. had extended its review period for three months because the company had submitted new data since an agency advisory panel have voted 12 to 1 in July that the approval should be rescinded.", "headline": {"main": "BUSINESS BRIEFING | REGULATORY AND LEGAL NEWS: F.D.A. Delays Ruling on Drug for Breast Cancer", "kicker": "PRESCRIPTIONS"}, "abstract": "Food and Drug Administration delays decision on whether to revoke approval of Genentech's drug Avastin as treatment for breast cancer (S)", "print_page": "2", "word_count": 995, "_id": "4fd29f158eb7c8105d8823d6", "snippet": "The Food and Drug Administration appears to have postponed an expected decision on whether to revoke the approval of the drug Avastin as a treatment for breast cancer.     Genentech, the manufacturer of the drug, said on Friday that the F.D.A. had...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9D0DE3D81E3DF93BA2575AC0A9669D8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "GENENTECH INC"}, {"name": "subject", "value": "BREASTS"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "AVASTIN (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2010-09-18T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": "The Food and Drug Administration appears to have postponed an expected decision on whether to revoke the approval of the drug Avastin as a treatment for breast cancer.", "headline": {"main": "F.D.A. Postpones Rule on Breast Cancer Drug", "kicker": "Prescriptions"}, "abstract": "he Food and Drug Administration appears to have postponed an expected decision on whether to revoke the approval of the drug Avastin as a treatment for breast cancer.", "print_page": null, "word_count": 1008, "_id": "4fd39c7e8eb7c8105d8dc8e2", "snippet": "he Food and Drug Administration appears to have postponed an expected decision on whether to revoke the approval of the drug Avastin as a treatment for breast cancer.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://prescriptions.blogs.nytimes.com/2010/09/17/f-d-a-postpones-rule-on-breast-cancer-drug/", "multimedia": [], "subsection_name": null, "keywords": [{"value": "News", "name": "type_of_material", "rank": "1"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "blogpost", "pub_date": "2010-09-17T18:51:11Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "By a 9-to-5 vote, the advisers decided that the potential benefits of the drug lorcaserin, from Arena Pharmaceuticals, did not outweigh risks.", "headline": {"seo": "Diet Drug From Arena Rejected by F.D.A. Panel", "main": "F.D.A. Panel Urges Denial of Diet Drug", "print_headline": "F.D.A. Panel Urges Denial Of Diet Drug"}, "abstract": null, "print_page": "1", "word_count": "936", "_id": "541ab3e379881037000b9b9a", "snippet": "By a 9-to-5 vote, the advisers decided that the potential benefits of the drug lorcaserin, from Arena Pharmaceuticals, did not outweigh risks.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2010/09/17/health/17drug.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Obesity", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Food and Drug Administration", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "Medicine and Health", "is_major": "N", "rank": "4", "name": "subject"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2010-09-17T00:00:00Z", "section_name": "Health"}, {"type_of_material": "Blog", "blog": [], "news_desk": null, "lead_paragraph": "A federal advisory committee Thursday voted against recommending approval of a new weight loss drug developed by Arena Pharmaceuticals.", "headline": {"main": "F.D.A. Panel Rejects Diet Pill", "kicker": "Prescriptions"}, "abstract": "An advisory committee voted against approving a weight-loss drug by Arena Pharmaceuticals, citing in part potential heath risks.", "print_page": null, "word_count": 686, "_id": "4fd39c1f8eb7c8105d8db9a5", "snippet": "An advisory committee voted against approving a weight-loss drug by Arena Pharmaceuticals, citing in part potential heath risks.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://prescriptions.blogs.nytimes.com/2010/09/16/f-d-a-panel-rejects-diet-pill-2/", "multimedia": [], "subsection_name": null, "keywords": [{"value": "News", "name": "type_of_material", "rank": "1"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "blogpost", "pub_date": "2010-09-16T15:54:28Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "National", "lead_paragraph": "After decades of debate, the Food and Drug Administration appears poised to issue stronger rules on antibiotics, intended to reduce what it calls a clear risk to humans.", "headline": {"seo": "U.S. Zeroes In on Use of Antibiotics by Pork Producers", "main": "U.S. Meat Farmers Brace for Limits on Antibiotics", "print_headline": "Meat Farmers Brace for Limits on Antibiotics"}, "abstract": null, "print_page": "14", "word_count": "1182", "_id": "541a970a79881037000b98f5", "snippet": "After decades of debate, the Food and Drug Administration appears poised to issue stronger rules on antibiotics, intended to reduce what it calls a clear risk to humans.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2010/09/15/us/15farm.html", "multimedia": [{"subtype": "xlarge", "url": "images/2010/09/15/us/15farm-span/15farm-span-articleLarge-v2.jpg", "height": 315, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2010/09/15/us/15farm-span/15farm-span-articleLarge-v2.jpg", "xlargeheight": "315"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2010/09/15/us/15farm-span/15farm-span-thumbStandard-v2.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2010/09/15/us/15farm-span/15farm-span-thumbStandard-v2.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Antibiotics", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Livestock", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Factory Farming", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Meat", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Food and Drug Administration", "is_major": "N", "rank": "5", "name": "organizations"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Erik", "lastname": "ECKHOLM"}], "original": "By ERIK ECKHOLM"}, "document_type": "article", "pub_date": "2010-09-15T00:00:00Z", "section_name": "U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "RALSTON, Iowa -- Piglets hop, scurry and squeal their way to the far corner of the pen, eyeing an approaching human. ''It shows that they're healthy animals,'' Craig Rowles, the owner of a large pork farm here, said with pride. Mr. Rowles says he keeps his pigs fit by feeding them antibiotics for weeks after weaning, to ward off possible illness in that vulnerable period. And for months after that, he administers an antibiotic that promotes faster growth with less feed.", "headline": {"main": "Meat Farmers Brace for Limits on Antibiotics"}, "abstract": null, "print_page": "14", "word_count": 1314, "_id": "4fd2b7318eb7c8105d8ab929", "snippet": "RALSTON, Iowa -- Piglets hop, scurry and squeal their way to the far corner of the pen, eyeing an approaching human. ''It shows that they're healthy animals,'' Craig Rowles, the owner of a large pork farm here, said with pride.     Mr. Rowles says he...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9905EFDA143AF936A2575AC0A9669D8B63", "multimedia": [], "subsection_name": null, "keywords": [], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Erik", "rank": 1, "lastname": "ECKHOLM"}], "original": "By ERIK ECKHOLM"}, "document_type": "article", "pub_date": "2010-09-15T00:00:00Z", "section_name": "U.S."}], "meta": {"hits": 9, "offset": 0, "time": 48}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}